All In Biotech

Drug Trial Radar · NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children

Last checked: Nov 19, 2026Latest source record: Sep 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,046 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,046

Actual

Start

Oct 1, 2011

Primary completion

Oct 31, 2014

Study completion Dec 31, 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 35 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age. Recruitment will encompass at least 4 independent cohorts: a first cohort in the Northern Hemisphere (2011-2012), a second cohort in subtropical countries (2012), third cohort in the Northern Hemisphere (2012-2013) and a fourth cohort and additional independent cohorts possibly in NH countries (end 2013) and subtropical countries (beginning 2014).

Conditions

  • Influenza

Interventions

  • Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138ABiological

    Intramuscular injection

  • Havrix JuniorBiological

    Intramuscular injection administered to subjects aged 12 months or older

  • Prevenar 13Biological

    Intramuscular injection administered to subjects less than 12 months of age

  • Varivax/ProVarivaxBiological

    Intramuscular injection administered to subjects more than 12 months of age

  • VarilrixBiological

    Subcutaneous injection administered to subjects more than 12 months of age

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza.Time frame: During the surveillance period (approximately 6 to 8 months)
  2. Number of Subjects With RT-PCR Confirmed Influenza of Any Severity.Time frame: During the surveillance period (approximately 6 to 8 months)

Locations

103 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Dhaka, Bangladesh

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Mechelen, Belgium

  • GSK Investigational Site

    Namur, Belgium

  • GSK Investigational Site

    Roeselaere, Belgium

  • GSK Investigational Site

    Turnhout, Belgium

  • GSK Investigational Site

    Děčín, Czechia

  • GSK Investigational Site

    Humpolec, Czechia

  • GSK Investigational Site

    Jindřichův Hradec, Czechia

  • GSK Investigational Site

    Liberec, Czechia

  • GSK Investigational Site

    Lipník nad Bečvou, Czechia

  • GSK Investigational Site

    Náchod, Czechia

  • GSK Investigational Site

    Odolena Voda, Czechia

  • GSK Investigational Site

    Ostrava - Poruba, Czechia

  • GSK Investigational Site

    Pardubice, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Tábor, Czechia

  • GSK Investigational Site

    Santo Domingo, Dominican Republic

  • GSK Investigational Site

    Santo Domingo, Distrito Nacional, Dominican Republic

  • GSK Investigational Site

    San Pedro Sula, Honduras

  • GSK Investigational Site

    Tegucigalpa, Honduras

  • GSK Investigational Site

    Faridabad, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Beirut, Lebanon

  • GSK Investigational Site

    City of Muntinlupa, Philippines

  • GSK Investigational Site

    Manila, Philippines

  • GSK Investigational Site

    Manila, Philippines

  • GSK Investigational Site

    Metro Manila, Philippines

  • GSK Investigational Site

    Quezon City, Philippines

  • GSK Investigational Site

    Sampaloc, Manila, Philippines

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Dębica, Poland

  • GSK Investigational Site

    Gdansk, Poland

  • GSK Investigational Site

    Grudziądz, Poland

  • GSK Investigational Site

    Katowice, Poland

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.